These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10519721)

  • 1. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease.
    de Montalembert M; Bégué P; Bernaudin F; Thuret I; Bachir D; Micheau M
    Arch Dis Child; 1999 Nov; 81(5):437-9. PubMed ID: 10519721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.
    Chaine B; Neonato MG; Girot R; Aractingi S
    Arch Dermatol; 2001 Apr; 137(4):467-70. PubMed ID: 11295927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
    Strouse JJ; Lanzkron S; Beach MC; Haywood C; Park H; Witkop C; Wilson RF; Bass EB; Segal JB
    Pediatrics; 2008 Dec; 122(6):1332-42. PubMed ID: 19047254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.
    Lanzkron S; Strouse JJ; Wilson R; Beach MC; Haywood C; Park H; Witkop C; Bass EB; Segal JB
    Ann Intern Med; 2008 Jun; 148(12):939-55. PubMed ID: 18458272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
    Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
    Zimmerman SA; Schultz WH; Davis JS; Pickens CV; Mortier NA; Howard TA; Ware RE
    Blood; 2004 Mar; 103(6):2039-45. PubMed ID: 14630791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease.
    de Montalembert M; Belloy M; Bernaudin F; Gouraud F; Capdeville R; Mardini R; Philippe N; Jais JP; Bardakdjian J; Ducrocq R; Maier-Redelsperger M; Elion J; Labie D; Girot R
    J Pediatr Hematol Oncol; 1997; 19(4):313-8. PubMed ID: 9256830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical follow-up of hydroxyurea-treated adults with sickle cell disease.
    Nzouakou R; Bachir D; Lavaud A; Habibi A; Lee K; Lionnet F; Hulin A; Jouault H; Préhu C; Roudot-Thoraval F; Girot R; Galactéros F
    Acta Haematol; 2011; 125(3):145-52. PubMed ID: 21196716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea in very young children with sickle cell anemia is not a cure-all.
    Powars DR
    J Pediatr; 2001 Dec; 139(6):763-4. PubMed ID: 11743496
    [No Abstract]   [Full Text] [Related]  

  • 10. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy.
    O'branski EE; Ware RE; Prose NS; Kinney TR
    J Am Acad Dermatol; 2001 May; 44(5):859-61. PubMed ID: 11312437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of Seminal Fluid Parameters and Fertility of Male Sickle Cell Disease Patients and Potential Impact of Hydroxyurea Treatment.
    Sahoo LK; Kullu BK; Patel S; Patel NK; Rout P; Purohit P; Meher S
    J Assoc Physicians India; 2017 Jun; 65(6):22-25. PubMed ID: 28782309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leg ulcer induced by hydroxycarbamide in sickle cell disease: What is the therapeutic impact?
    Soya E; Makowski C; Blaise S
    Int Wound J; 2019 Aug; 16(4):897-902. PubMed ID: 30916480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea in Sickle Cell Disease and Invasive Bacterial Infections: A Case-Control Study.
    Pascault A; Koehl B; Brousse V; Benkerrou M; Gaschignard J
    J Pediatric Infect Dis Soc; 2024 Sep; 13(9):493-495. PubMed ID: 38970408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know.
    Rees AL
    J Pediatr Oncol Nurs; 2016 Sep; 33(5):339-44. PubMed ID: 26611755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxurea and sickle cell disease: Its been a long, long time coming.
    Scott JP
    Pediatr Blood Cancer; 2010 Feb; 54(2):185-6. PubMed ID: 19908298
    [No Abstract]   [Full Text] [Related]  

  • 17. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea.
    Wilson S
    Ann Intern Med; 2000 Dec; 133(11):925-6. PubMed ID: 11103075
    [No Abstract]   [Full Text] [Related]  

  • 19. Malignancies in sickle cell disease patients treated with hydroxyurea.
    Ferster A; Sariban E; Meuleman N;
    Br J Haematol; 2003 Oct; 123(2):368-9. PubMed ID: 14531924
    [No Abstract]   [Full Text] [Related]  

  • 20. Hydroxyurea for sickle-cell anaemia in Africa: mind the gap.
    Obaro SK
    Lancet Glob Health; 2015 Mar; 3(3):e124-5. PubMed ID: 25701988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.